


# Patent claims

## 1. Compounds of the formula I



wherein

15  $R^1$  is H, OH, OA, CN, Hal, COR or  $CH_2R$ ,

$R$  is by OH, OA,  $NH_2$ , NHA or  $NA_2$ ,

20  $R^2$  and  $R^3$  are H or A,

A is an alkyl group with 1–10 atoms,

25 X is O or S,

Hal is F, Cl, Br or I

$n$  is 2-6,

30  $m$  is 1-4

$p$  is 0, 1, 2, 3 or 4

35

and their salts, enantiomers, solvates, racemates and other mixtures of enantiomeres.


- 5           2. Compounds according to claim 1, wherein  $R^1$  is F or CN.
3. Compounds according to claim 1 or claim 2, wherein  $R^3$  is H.
- 10          4. Compounds according to one or more of the claims 1 to 3, wherein X is S or O.
5. Compounds according to one or more of the claims 1 to 4, wherein p is
- 15          0 or 1 or 2 or 3 or 4.
6. Indol derivatives according to one or more of the proceeding claims selected from the following group of compounds I1 to I5:

20

25


30

35




I1

5




I2

10




I3

15



I4

20



I5

25

and their salts, solvates, enantiomers and racemates.

30

7. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as pharmaceutical active compounds.

35

8. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as ligands of the 5HT-Receptor.
- 5 9. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as serotonin reuptake inhibitor.
- 10 10. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates 5HT1A antagonists.
11. Compounds of the formula I according to Claim 1 and their  
15 physiologically acceptable salts or solvates for use in the control of diseases.
12. Pharmaceutical preparation characterized in that it contains at least  
20 one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts or solvates.
13. Use of compounds of the formula I according to Claim 1 and/or their  
25 physiologically acceptable salts or solvates for the production of a medicament.
14. Use of compounds according to Claim 1 and/or their physiologically  
30 acceptable salts or solvates, enantiomeres or recemates for the production of a medicament for the treatment of illnesses which can be influenced by the binding of the compound of formula I to the 5-HT receptors.
15. Use of compounds according to Claim 1 and/or their physiologically  
35 acceptable salts or solvates, enantiomeres or recemates for the production of a medicament for the treatment of illnesses of the central

nervous system, in particular of mental disorders of the schizophrenia type and for the control of psychotic anxiety states.

5

10

15

20

25

30

35